Chai Discovery
1 open Forward Deployed Engineer role at Chai Discovery. Curated with comp bands.
On the board since Jul 2026 · still hiring
Our take
Why Chai Discovery
The rare bio-AI FDE seat — you're the bridge between frontier molecular models and big-pharma scientists, at a company that just raised $400M.
- FDE type
- True forward-deployed
- Travel
- Medium
- Comp
- Undisclosed
- Stage
- Late-stage
A good fit if you're…
- Engineers with computational biology or chemistry exposure
- People who want AI with physical-world stakes in drug discovery
- Those comfortable being the technical face to pharma scientists
What they do
Chai Discovery builds foundation models for molecular structure and design; its Chai-2 model drew attention for zero-shot antibody design. It closed a reported $400M Series C in July 2026 at a ~$3.8B valuation, led by Index with Kleiner Perkins, Sequoia and others, and has announced partnerships with Lilly, Pfizer and Novartis.
What “forward deployed” means here
You embed with biopharma partner teams and wire Chai's models into their wet-lab and in-silico workflows — standing up systems and clearing whatever blocks adoption. A parallel Forward-Deployed Scientist role exists, so the engineer seat likely owns pipelines, infra and integration while the scientist owns the biology; clarify that boundary in interviews.
Comp & leveling
No band is posted. Fresh $400M capital means the company can pay competitively, but pharma-facing roles often anchor lower than pure AI-infra; push for lab-tier cash plus meaningful equity given the stage.
Growth signals
Going from Series B to a ~$3.8B Series C in roughly seven months, with three top-20 pharma deals, is about as strong a signal as bio-AI gets. The honest risk: drug discovery validates on multi-year timelines, so commercial proof lags the hype.
Analysis updated 2026-09-25
Open roles at Chai Discovery
Compare Chai Discovery
Others in the same tier
Free forever. Unsubscribe anytime.